UroGen Pharma announced strong preliminary results from its Phase 3 UTOPIA trial for UGN-103, showing a 77.8% three-month complete response rate for patients with recurrent low-grade intermediate-risk ...

Photocure ASA ( ($PHCUF) ) has released its Q3 earnings. Here is a breakdown of the information Photocure ASA presented to its investors.

Despite majoring in engineering, a Cranberry Township woman took on a health-related project when applying to graduate school ...

Merck (NYSE:MRK) announced on Thursday that the FDA has granted priority review for two of its marketing applications aimed at expanding the U.S. indications of injectable and intravenous versions of ...